Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.
Failure in cancer drug development exacts heavy burdens on patients and research systems. To investigate inefficiencies and burdens in targeted drug development in cancer, we conducted a systematic review of all prelicensure trials for the anticancer drug, sorafenib (Bayer/Onyx Pharmaceuticals). We...
Saved in:
| Main Authors: | James Mattina, Benjamin Carlisle, Yasmina Hachem, Dean Fergusson, Jonathan Kimmelman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-02-01
|
| Series: | PLoS Biology |
| Online Access: | https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.2000487&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments.
by: Valerie C Henderson, et al.
Published: (2013-01-01) -
HPLC-UV method development and validation for anticancer drug sorafenib and the co-prescribed drug dexamethasone: application to pharmacokinetic evaluation of sorafenib nanoformulations
by: Abdul Mateen, et al.
Published: (2025-04-01) -
Folic Acid-Targeted Liposome-Based Nanoparticle Loaded with Sorafenib for Liver Cancer Therapy
by: Liu S, et al.
Published: (2025-03-01) -
Inefficiency and Gaps in Financial Stability in sub-Saharan Africa
by: Evans Kulu, et al.
Published: (2022-12-01) -
The problems of inefficient use of budget funds
by: S. V. Frumina
Published: (2020-01-01)